Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of Pandemic Vaccines: ERVEBO Case Study.
Wolf J, Jannat R, Dubey S, Troth S, Onorato MT, Coller BA, Hanson ME, Simon JK. Wolf J, et al. Among authors: coller ba. Vaccines (Basel). 2021 Feb 25;9(3):190. doi: 10.3390/vaccines9030190. Vaccines (Basel). 2021. PMID: 33668698 Free PMC article. Review.
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.
Manoff SB, Sausser M, Falk Russell A, Martin J, Radley D, Hyatt D, Roberts CC, Lickliter J, Krishnarajah J, Bett A, Dubey S, Finn T, Coller BA. Manoff SB, et al. Among authors: coller ba. Hum Vaccin Immunother. 2019;15(9):2195-2204. doi: 10.1080/21645515.2018.1546523. Epub 2019 Jun 3. Hum Vaccin Immunother. 2019. PMID: 30427741 Free PMC article. Clinical Trial.
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Among authors: coller ba. Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11. Vaccine X. 2019. PMID: 31384731 Free PMC article.
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
Halperin SA, Das R, Onorato MT, Liu K, Martin J, Grant-Klein RJ, Nichols R, Coller BA, Helmond FA, Simon JK; V920-012 Study Team. Halperin SA, et al. Among authors: coller ba. J Infect Dis. 2019 Aug 30;220(7):1127-1135. doi: 10.1093/infdis/jiz241. J Infect Dis. 2019. PMID: 31505665 Free PMC article. Clinical Trial.
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
Badio M, Lhomme E, Kieh M, Beavogui AH, Kennedy SB, Doumbia S, Leigh B, Sow SO, Diallo A, Fusco D, Kirchoff M, Termote M, Vatrinet R, Wentworth D, Esperou H, Lane HC, Pierson J, Watson-Jones D, Roy C, D'Ortenzio E, Greenwood B, Chêne G, Richert L, Neaton JD, Yazdanpanah Y; PREVAC study team. Badio M, et al. Trials. 2021 Jan 23;22(1):86. doi: 10.1186/s13063-021-05035-9. Trials. 2021. PMID: 33485369 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33580080
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
Morozov I, Monath TP, Meekins DA, Trujillo JD, Sunwoo SY, Urbaniak K, Kim IJ, Narayanan SK, Indran SV, Ma W, Wilson WC, O'Connor C, Dubey S, Troth SP, Coller BA, Nichols R, Martin BK, Feldmann H, Richt JA. Morozov I, et al. Among authors: coller ba. Emerg Microbes Infect. 2021 Dec;10(1):651-663. doi: 10.1080/22221751.2021.1903343. Emerg Microbes Infect. 2021. PMID: 33719915 Free PMC article.
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Grais RF, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BA, Welebob C, Hanson ME, Simon JK. Grais RF, et al. Among authors: coller ba. Lancet Microbe. 2021 Feb;2(2):e70-e78. doi: 10.1016/S2666-5247(20)30198-1. Epub 2021 Feb 2. Lancet Microbe. 2021. PMID: 35544244 Free article.
45 results